狠狠色丁香久久综合婷婷亚洲成人福利在线-欧美日韩在线观看免费-国产99久久久久久免费看-国产欧美在线一区二区三区-欧美精品一区二区三区免费观看-国内精品99亚洲免费高清

            深圳市科潤達(dá)生物工程有限公司
            中級會員 | 第17年

            15711973608

            當(dāng)前位置:首頁   >>   資料下載   >>   Z大限度發(fā)揮血清β淀粉酶檢測在老年癡呆癥的診斷中的作用

            Z大限度發(fā)揮血清β淀粉酶檢測在老年癡呆癥的診斷中的作用

            時間:2010-3-9閱讀:1775
            分享:
            • 提供商

              深圳市科潤達(dá)生物工程有限公司
            • 資料大小

              0K
            • 資料圖片

            • 下載次數(shù)

              231次
            • 資料類型

              PDF 文件
            • 瀏覽次數(shù)

              1775次
            點擊免費下載該資料

            zui大限度發(fā)揮血清β淀粉酶檢測在老年癡呆癥的診斷中的作用

            Neuromolecular Med. 2008 ; 10(3): 195–207. doi:10.1007/s12017-008-8035-0.

            Maximizing the Potential of Plasma Amyloid-beta as a Diagnostic
            Biomarker for Alzheimer’s Disease

            Esther S. Oh, M.D.a,b*, Juan C. Troncoso, M.D.b,c, and Stina M. Fangmark Tucker, Ph.D.
            aDepartment of Medicine, The Johns Hopkins University School of Medicine, 558 Ross Research Building,
            720 Rutland Ave., Baltimore, MD
            bDepartment of Pathology, The Johns Hopkins University School of Medicine, 558 Ross Research Building,
            720 Rutland Ave., Baltimore, MD
            cDepartment of Neurology, The Johns Hopkins University School of Medicine, 558 Ross Research Building,
            720 Rutland Ave., Baltimore, MD
            Abstract
            Amyloid plaques are composed primarily of amyloid-beta (Aβ) peptides derived from proteolytic
            cleavage of amyloid precursor protein (APP), and are considered to play a pivotal role in Alzheimer's
            disease (AD) pathogenesis. Presently, AD is diagnosed after the onset of clinical manifestations.
            With the arrival of novel therapeutic agents for treatment of AD, there is an urgent need for
            biomarkers to detect early stages of AD. Measurement of plasma Aβ has been suggested as an
            inexpensive and non-invasive tool to diagnose AD and to monitor Aβ modifying therapies. However,
            the majority of cross-sectional studies on plasma Aβlevels in humans have not shown differences
            between individuals with AD compared to controls. Similarly, cross-sectional studies of mouse
            plasma Aβ have yielded inconsistent trends in different mouse models. However, longitudinal studies
            appear to be more promising in humans. Recently, efforts to modify plasma Aβ levels using
            modulators have shown some promise. In this review, we will summarize the present data on plasma
            Aβ in humans and mouse models of AD. We will discuss the potential of modulators of Aβ levels
            in plasma including antibodies and insulin, and the challenges associated with measuring plasma
            Aβ. Modulators of plasma Aβ may provide an important tool to optimize plasma Aβ levels, and may
            improve the diagnostic potential of this approach.

            會員登錄

            ×

            請輸入賬號

            請輸入密碼

            =

            請輸驗證碼

            收藏該商鋪

            X
            該信息已收藏!
            標(biāo)簽:
            保存成功

            (空格分隔,最多3個,單個標(biāo)簽最多10個字符)

            常用:

            提示

            X
            您的留言已提交成功!我們將在第一時間回復(fù)您~
            撥打電話
            在線留言